why choose us

First received: October 31, 2023

Clinical Trial: A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Carcinoma, Non-small-Cell Lung

Study Type: INTERVENTIONAL


Official Title: A Phase 1 Study of JNJ-86974680, an A2a Receptor Antagonist, Administered as Monotherapy and in Combination With Cetrelimab and Radiotherapy for Advanced Non-small Cell Lung Cancer

Brief Summary: The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.

Read more